-
These new technologies win gold and silver in Geneva
Time of Update: 2022-05-11
The 2022 Geneva International Exhibition of Inventions, jointly organized by the World Intellectual Property Organization and the Swiss Federal Government, will be held online in March .
-
Roche and Teva reach innovative strategic cooperation to expand blood and tumor pipeline
Time of Update: 2022-05-08
Roche Pharma China announced on April 18 that it has reached a cooperation with Teva Pharmaceuticals (hereinafter referred to as "Teva") to expand the patient access of bendamustine
-
Pfizer, GlaxoSmithKline and Teva lead price hikes on more than 400 drugs in 2022
Time of Update: 2022-01-26
The data for the first week of the new year in 2022 is closer to 2020, when 463 drug prices rose before January 3, so analysts expect the number and increases in January's drug rises may continue over time.
-
2019 Annual Meeting of the American Academy of Neurology: Teva will announce the long-term efficacy and safety data of Fremanezumab
Time of Update: 2021-12-03
prevention Fremanezumab is a fully humanized monoclonal antibody directed against calcitonin gene-related peptide ( CGRP ) α and β .
-
J Thromb Haemost: The Pregnancy Adaptation Geneva (PAG) Score is used to assess the clinical probability of pulmonary embolism during pregnancy
Time of Update: 2021-09-19
Among pregnant women with suspected PE, the PAG score has a high discrimination ability to identify patients with low, medium, or high PTP .
-
Teva multiple sclerosis blockbuster application for listing in China
Time of Update: 2021-08-08
According to reports in the literature, an open study that has been conducted for 6 years shows that glatiramer acetate injection can alleviate the recurrence rate of patients with multiple sclerosis and reduce the rate of disease development .
-
Sci Immun: Geneva and Harvard University found a new immunotherapy without side effects
Time of Update: 2021-08-01
Inhibiting neutrophils may be a more effective way to fight cancer: in addition to triggering a toxic response, some of these cells also promote tumor growth .
-
Pfizer, Novartis, Sanofi, Takeda, Teva and many other rare disease new drugs have been listed in China and have been included in medical insurance
Time of Update: 2021-07-23
Laronie Enzyme Concentrate Solution for Injection (trade name: Aldurazyme) for the diagnosis of mucopolysaccharidosis type I (MPS Ⅰ) Long-term enzyme replacement therapy for patients, for the treatment of non-neurological manifestations
-
Johnson & Johnson, AbbVie, Teva and Endo face $50 billion opioid lawsuits
Time of Update: 2021-07-09
Oklahoma believes that the aggressive marketing strategies of Johnson & Johnson and other companies have led to the proliferation of opioid prescriptions in the state .
-
Teva again initiates patent lawsuit against Eli Lilly over migraine drug Emgality
Time of Update: 2021-06-16
Up to now, there have been three monoclonal antibody migraine preventive drugs that target CGRP or its receptors: Novartis and Amgen Aimovig, Eli Lilly Emgality and Teva Ajovy .
-
Johnson & Johnson, AbbVie, Teva and Endo face $50 billion opioid lawsuits
Time of Update: 2021-05-10
Oklahoma believes that the aggressive marketing strategies of Johnson & Johnson and other companies have led to the proliferation of opioid prescriptions in the state.
-
In response to fierce generic competition, the Teva Israel plant cut 350 jobs
Time of Update: 2021-03-05
We are confident that this process will restore the Neot-Havav plant to competitiveness and enable us to continue to increase the strategic focus of Israel's global activities in Teva.
-
IONTAS and Teva announce new antibody optimization protocols
Time of Update: 2021-02-25
Under the terms of the agreement, IONTAS will first use its proprietary technology to provide Teva with a specific set of optimized antibodies.
-
Sword refers to Roche Hessetin! Celltrion/Teva biosimilar Herzuma (Curto bead monoanti) has been approved by the FDA:
Time of Update: 2021-02-17
South Korean biopharmaceutical company Celltrion and partner Teva recently announced that the U.S. Food and Drug Administration (FDA) has approved the trastuzumab-pkrb, an anti-biosimilar, for HER2-positive breast cancer treatment.
-
K.O.！ Novartis multiple sclerosis drug Gilenya's first head-to-head Phase III study beats Teva's super-heavy product Co.
Time of Update: 2021-02-14
, Copaxone 20mg treatment queue. data show that Gilenya 0.5mg significantly reduced the annual recurrence rate (ARR) by 40.7% over the one-year treatment period (ARR valuation: 0.153 vs 0258, p=0.0138). Further preliminary results showed
-
Global generics giant Teva has teamed up with Takeda to create a new company in Japan to promote high-quality generics
Time of Update: 2021-02-13
will operate as an independent company with its own board of directors, chief executive officer and executive leadership team. Further details of the cooperation between the two sides have not been disclosed. Given that the deal will not take effect until
-
In response to fierce generic competition, the Teva Israel plant cut 350 jobs.
Time of Update: 2020-10-04
we believe this process will restore the Neot-Havav plant to competitiveness and enable us to continue to increase the strategic focus of Israel's global activities in Teva.
-
Teva is in legal trouble again, this time for allegedly defrauding Medicare!
Time of Update: 2020-09-29
hundreds of millions of dollars to two foundations as part of a plan to boost the sale of its multiple sclerosis drug Copaxone, an injection of acetic acid. , according to a complaint filed in U.S. District Court in Massachusetts, Teva paid more
-
350 jobs to be cut at Teva Israel plant in response to fierce generic competition.
Time of Update: 2020-09-27
we believe this process will restore the Neot-Havav plant to competitiveness and enable us to continue to increase the strategic focus of Israel's global activities in Teva.
-
New migraine drug! Teva/Otsuka Japan submits Ajovy listing application, Teva/Takeda Japan joint venture sells generic drug assets!
Time of Update: 2020-08-06
"This is an exciting milestone that will deliver on our global mission to improve patients' lives by advancing potential new treatments," said Gianfranco Nazzi, executive vice president of Teva International Markets.
